This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 ...

An award-winning pathologist who devoted his life to melanoma research became the first person to receive a novel ...

Neurodegenerative disorders have increasing incidence with limited treatment options. Approaches to target neuroinflammation in various neurodegenerative disorders, such as Alzheimer’s disease (AD), ...

Biogen BIIB announced that the FDA has granted fast track designation to its investigational Alzheimer's disease (AD) drug, ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study. BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab ...

Today, there is no approved pill that can reliably treat severe obesity on its own. Obesity affects over 40% of adults in the United States and is linked to serious health issues like heart disease, ...

In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month ...

An experimental treatment appears to postpone Alzheimer's symptoms in some people genetically destined to get the disease at ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a midstage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.